26.29
-0.10 (-0.38%)
Previous Close | 26.39 |
Open | 26.07 |
Volume | 1,293,659 |
Avg. Volume (3M) | 1,205,568 |
Market Cap | 2,176,959,232 |
Price / Sales | 5.74 |
Price / Book | 2.56 |
52 Weeks Range | |
Earnings Date | 25 Feb 2025 - 3 Mar 2025 |
Profit Margin | -41.07% |
Operating Margin (TTM) | -746.40% |
Diluted EPS (TTM) | -1.58 |
Quarterly Revenue Growth (YOY) | -17.00% |
Total Debt/Equity (MRQ) | 20.48% |
Current Ratio (MRQ) | 5.69 |
Operating Cash Flow (TTM) | -135.81 M |
Levered Free Cash Flow (TTM) | -38.55 M |
Return on Assets (TTM) | -9.27% |
Return on Equity (TTM) | -18.29% |
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Mixed |
Biotechnology (Global) | Mixed | Mixed | |
Stock | Beam Therapeutics Inc. | Bullish | Bullish |
AIStockmoo Score
Analyst Consensus | 1.5 |
Insider Activity | NA |
Price Volatility | -1.0 |
Technical Moving Averages | -2.5 |
Technical Oscillators | 2.0 |
Average | 0.00 |
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Value |
% Held by Insiders | 1.48% |
% Held by Institutions | 93.21% |
Ownership
Name | Date | Shares Held |
---|---|---|
Mwg Management Ltd. | 30 Sep 2024 | 2,266,934 |
52 Weeks Range | ||
Median | 80.00 (204.30%) | |
Total | 1 Buy |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
HC Wainwright & Co. | 03 Feb 2025 | 80.00 (204.30%) | Buy | 25.59 |
09 Dec 2024 | 80.00 (204.30%) | Buy | 27.52 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |